Predictive value of 18F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation

Hematology

Volumn 15, Issue 1, 2010, Pages 21-27

  Qiao, Wenli ^a   Zhao, Jinhua ^a   Wang, Chun ^a   Wang, Taisong ^a   Xing, Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Autologous stem cell TRANSPLANTATION; Fluorine 18 fluorodeoxyglucose; Hybrid pet ct; Non hodgkin's lymphoma; PROGRESSION FREE SURVIVAL

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; MORTALITY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; TENIPOSIDE; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 76749147881     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347009739     Document Type: Article

References (23)

1. Canellos GP. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 1997; 15(5):1713-1716.
2. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25(4): 483-491.
3. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(23):1540-1545.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329(14): 987-994.
5. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11(5): 931-936.
6. Gordon BG, Warkentin PI, Weisenburger DD et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood 1992, 80(11): 2938-2942.
7. Becherer A, Mitterbauer M, Jaeger U et al. Positron emission tomography with [18F]2-fouoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16(2): 260-267.
8. Cremerius U, Fabry U, Wildberger JE et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. BoneMarrow Transplant 2002; 30(2): 103-111.
9. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102(1): 53-59.
10. Filmont JE, Czernin J, Yap C et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124(2): 608-613.
11. Schot B, van Imhoff G, Pruim J et al. Predictive value of early 18Ffluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003, 123(2): 282-287.
12. Schot BW, Pruim J, van Imhoff GW. The role of serial pretransplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91(4): 490-495.
13. Svoboda J, Andreadis C, Elstrom R. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38(3): 211-216.
14. Yoshimi A, Izutsu K, Takahashi M et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol 2008; 83(6): 477-481.
15. Crocchiolo R, Canevari C, Assanlli A et al. Pre-transplant 18FDGPET predicts outcome in lymphoma patients treated with highdose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008; 49(4): 727-733.
16. Jerusalem G, Hustinx R, Beguin Y et al. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35(3): 186-196.
17. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16(9): 1514-1523.
18. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106(4): 1376-1381.
19. Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1): 22-28.
20. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19(2): 414-419.
21. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16(9): 1514-1523.
22. Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1): 22-28.
23. Filmont JE, Gisselbrecht C, Cuenca X et al. The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stemcell transplantation. Cancer 2007; 110(6): 1361-1369.